Lack of change in basal ganglia neuropeptide content following subacute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of the common marmoset.
Treatment of common marmosets with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP; 1-4 mg/kg for up to 4 days) caused a profound parkinsonian state. Ten days from the start of MPTP treatment, all animals showed marked motor impairment, consisting of bradykinesia and akinesia, limb rigidity, postural abnormalities, loss of vocalisation and blink reflex, and, on occasions, postural tremor. Measurement of caudate-putamen monoamine content at this time showed a profound loss in 3,4-dihydroxyphenylethylamine, homovanillic acid, and 3,4-dihydroxyphenylacetic acid concentrations. Measurement of neuropeptide concentrations in the caudate-putamen, internal and external segments of the globus pallidus, nucleus accumbens, substantia nigra, frontal cortex, and hippocampus showed met-enkephalin, leu-enkephalin, and cholecystokinin (CCK-8) concentrations to be unaffected by MPTP treatment. There was a small decrease in the substance P content of frontal cortex, but otherwise the content of this neuropeptide was unaltered. Parkinsonism in the marmoset, induced by MPTP treatment 10 days earlier, does not alter neuropeptide concentrations in the manner observed in Parkinson's disease.
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D001479:Basal Ganglia / Q000032:analysis / Q000187:drug effects*; D001522:Behavior, Animal / Q000187:drug effects; D002143:Callitrichinae; D002421:Caudate Nucleus / Q000187:drug effects / Q000378:metabolism; D004743:Enkephalin, Leucine / Q000378:metabolism; D004744:Enkephalin, Methionine / Q000378:metabolism; D005260:Female; D006719:Homovanillic Acid / Q000378:metabolism; D008297:Male; D009479:Neuropeptides / Q000032:analysis*; D011699:Putamen / Q000187:drug effects / Q000378:metabolism; D011725:Pyridines / Q000494:pharmacology*; D012844:Sincalide / Q000494:pharmacology; D013373:Substance P / Q000378:metabolism
D009479:Neuropeptides; D011725:Pyridines; D015102:3,4-Dihydroxyphenylacetic Acid; D013373:Substance P; D004744:Enkephalin, Methionine; D004743:Enkephalin, Leucine; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D012844:Sincalide; D006719:Homovanillic Acid